April 2019 Vol 5 No 2
FDA Approvals, News & UpdatesGastric Cancer
In February 2019, the FDA approved Lonsurf for the treatment of patients with metastatic gastric (stomach) cancer or gastroesophageal junction adenocarcinoma. This drug was previously approved only for patients with metastatic colorectal cancer.
By Dana Taylor
Results of a recent study showed that using the targeted therapy Imbruvica (ibrutinib) as the first treatment in older adults with CLL was better than the combination of chemotherapy plus immunotherapy in slowing the progression of the disease.
Clinical TrialsPatient StoriesSkin Cancer
After a lifetime of treating patients, Dr. David Crouch understood his own illness left little room for optimism as skin cancer returned again and again. As a last resort, he joined a clinical trial of a new immunotherapy that provided him a new lease on life. Today, after 2 years in remission, his mission is to educate people about this cancer and this immunotherapy.
From Your Navigator
Longtime nurse navigator Sharon Gentry describes how a nurse navigator will help ensure you get the best possible care during your treatment and beyond. The article includes useful sources and a handy chart for easy reference.
Infusion of Hope
Tom Galioto, a volunteer at his local Tri-Cities Cancer Center in Kennewick, Washington, has always recognized the importance of maintaining a positive outlook and a sense of humor even in the face of a cancer diagnosis. He shares some of his favorite “inspirology” sayings, offering guidance and levity in making your challenges a little lighter.
Adam Balinsky, President of Fifth Season Financial, discusses the company’s Funds for Living and Giving program, which provides financial help for people with advanced cancer by leveraging their existing life insurance policy.
FDA Approvals, News & UpdatesLeukemia
FDA Approves Imbruvica plus Gazyva for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This new chemotherapy-free combination of Imbruvica, a targeted therapy, plus Gazyva, a CD20-directed cytolytic antibody, was recently approved by the FDA as first-line treatment of adults aged 65 or older who are newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Page 2 of 2
Results 11 - 19 of 19
Results 11 - 19 of 19